Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016

Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus

Daniel C. PayneComments to Author , Ibrahim Iblan, Brian Rha, Sultan Alqasrawi, Aktham Haddadin, Mohannad Al Nsour, Tarek Alsanouri, Sami Sheikh Ali, Jennifer Harcourt, Congrong Miao, Azaibi Tamin, Susan I. Gerber, Lia M. Haynes, and Mohammad Mousa Al Abdallat
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D.C. Payne, B. Rha, J. Harcourt, C. Miao, A. Tamin, S.I. Gerber, L.M. Haynes); Jordan Field Epidemiology Training Program, Amman, Jordan (I. Iblan); Jordan Ministry of Health, Amman (S. Alqasraw, A. Haddadin, T. Alsanouri, S. Sheikh Ali, M.M. Al Abdallat); Eastern Mediterranean Public Health Network, Amman (M. Al Nsour, T. Alsanouri)

Main Article


Characteristics of Middle East respiratory syndrome patients and antibody titers at 13 and 34 months after 2012 outbreak, Jordan*

Patient no. Age, y/sex Underlying
condition Intensive
care Days
hospitalized Chest
radiograph† 13-mo titer‡
34-mo titer‡
02 31/M Atrial septal defect Yes 16 Right lobar pneumonia >6,400 Pos 160 1,600 Pos 80
03§ 60/M Hypertension NA NA Bilateral consolidation; pneumonia 400 Pos 20 <400 Ind 20
04 35/M Hypertension Yes 8 Bilateral lobar pneumonia >6,400 Pos 80 400 Pos 40
06 46/M None
reported No 6 Right bronchial congestion with
bronchovascular markings 1,600 Pos 20 1,600 Pos 20
09 45/M None
reported No 10 Left consolidation; right infiltrate 400 Pos 40 <400 Neg 40
11¶ 41/F None
reported No 4 ND 1,600 Pos <20 400 Neg <20
HH303§ 39/F Pregnant NA NA NA 1,600 Pos 80 400 Pos 80

*IFA, immunofluorescence assay; Ind, indeterminate; MN, microneutralization assay; NA, not applicable; ND, not documented; neg, negative; pos, positive.
†Taken within 3 days of presentation.
‡Antibodies against Middle East respiratory syndrome coronavirus.
§Symptomatic but refused hospitalization.
¶Classified overall as being serologically negative at 34 mo.

Main Article

Page created: September 20, 2016
Page updated: September 20, 2016
Page reviewed: September 20, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.